Torque teno virus (TTV), long considered an orphan hepatotropicvirus, has been reconsidered in the last decade as a lymphotropicvirus. As viremia is almost universally acquired very early in age,it is an ideal marker for case–control functional studies. It hasbeen reported that patients with immune deficiencies of variousetiologies (human immunodeficiency virus or other chronic infec-tions, autoimmune diseases, and cancers) have very high viremias,suggesting break of immunosurveillance. In patients undergoinghigh-dose chemotherapy supported by autologous hematopoieticstem cell transplantation, our group has shown that kinetics ofcome-back to normal viremia parallel functional immunologicalreconstitution, assessed as percentage of ‘senescent’ CD57+Tlymphocytes. In this study peripheral blood samples of 46 liverrecipients, 90 kidney recipients (40 from deceased donors and50 from living donors), 19 simultaneous pancreas–kidney recip-ients, and 8 pancreas transplant recipients (3 primary and 5 aftera previous kidney transplant) were tested for TTV viremia byquantitative real-time polymerase chain reaction before trans-plant and then at month+1,+3,+6,+12, and+24. Medicalhistory about baseline disease and type of induction and mainte-nance immunosuppression were collected. We found that, acrossall solid organ transplant types, TTV viremia levels are relatedto the type of induction immunosuppression administered (ATGvsbasiliximab), and correlate with the number of cell-mediatedrejection episodes. Furthermore, at the same pharmacologicaldose of immunosuppressant, TTV viremia varies among recip-ients, suggesting that its value could be a quick and useful guidefor dose intensity.
Torquetenovirus viremia kinetics as a novel marker of functional immune deficiency in solid organ transplantation
Macera L;Vistoli F;Boggi U;Pistello M;Maggi F
2013-01-01
Abstract
Torque teno virus (TTV), long considered an orphan hepatotropicvirus, has been reconsidered in the last decade as a lymphotropicvirus. As viremia is almost universally acquired very early in age,it is an ideal marker for case–control functional studies. It hasbeen reported that patients with immune deficiencies of variousetiologies (human immunodeficiency virus or other chronic infec-tions, autoimmune diseases, and cancers) have very high viremias,suggesting break of immunosurveillance. In patients undergoinghigh-dose chemotherapy supported by autologous hematopoieticstem cell transplantation, our group has shown that kinetics ofcome-back to normal viremia parallel functional immunologicalreconstitution, assessed as percentage of ‘senescent’ CD57+Tlymphocytes. In this study peripheral blood samples of 46 liverrecipients, 90 kidney recipients (40 from deceased donors and50 from living donors), 19 simultaneous pancreas–kidney recip-ients, and 8 pancreas transplant recipients (3 primary and 5 aftera previous kidney transplant) were tested for TTV viremia byquantitative real-time polymerase chain reaction before trans-plant and then at month+1,+3,+6,+12, and+24. Medicalhistory about baseline disease and type of induction and mainte-nance immunosuppression were collected. We found that, acrossall solid organ transplant types, TTV viremia levels are relatedto the type of induction immunosuppression administered (ATGvsbasiliximab), and correlate with the number of cell-mediatedrejection episodes. Furthermore, at the same pharmacologicaldose of immunosuppressant, TTV viremia varies among recip-ients, suggesting that its value could be a quick and useful guidefor dose intensity.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
